| Unknown | Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis NCT06213909 | Xijing Hospital | — |
| Completed | Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid NCT05984381 | All India Institute of Medical Sciences, Bhubaneswar | Phase 4 |
| Terminated | A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult P NCT05681481 | argenx | Phase 3 |
| Unknown | Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid NCT05594472 | Cairo University | Phase 3 |
| Completed | Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid NCT05649579 | Peking University First Hospital | — |
| Not Yet Recruiting | Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid NCT05366127 | University Hospital, Rouen | — |
| Completed | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid NCT05267600 | argenx | Phase 2 / Phase 3 |
| Withdrawn | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARR NCT05061771 | AKARI Therapeutics | Phase 3 |
| Recruiting | Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid NCT06479018 | CHU de Reims | N/A |
| Completed | JAK Inhibitors' Efficacy in Bullous Pemphigoid NCT06561256 | Chao Ji | — |
| Terminated | A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. NCT04612790 | AstraZeneca | Phase 3 |
| Completed | Telederm and Bullous Pemphigoid NCT04728854 | Emory University | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid NCT04206553 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody NCT04563923 | Centre Hospitalier Universitaire de Nice | Phase 2 |
| Unknown | Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy NCT04641884 | Nantes University Hospital | — |
| Completed | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid NCT04117932 | CHU de Reims | Phase 2 |
| Unknown | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid NCT03926377 | Centre Hospitalier Universitaire, Amiens | Phase 4 |
| Unknown | Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? NCT03636763 | Assistance Publique Hopitaux De Marseille | — |
| Completed | Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid NCT03272958 | University Hospital, Brest | — |
| Terminated | A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid NCT03286582 | TWi Biotechnology, Inc. | Phase 2 |
| Completed | Ixekizumab in the Treatment of Bullous Pemphigoid NCT03099538 | Mayo Clinic | Phase 2 |
| Unknown | Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus NCT05284929 | Sechenov University | — |
| Withdrawn | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid NCT04128176 | University of California, Davis | Phase 3 |
| Recruiting | Autoimmune Blistering Diseases Study NCT02753777 | University of Pennsylvania | — |
| Unknown | Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid NCT02874079 | CHU de Reims | N/A |
| Completed | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid NCT02360202 | University Hospital, Rouen | Phase 4 |
| Completed | Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients NCT03320798 | CHU de Reims | — |
| Completed | Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid NCT02837965 | CHU de Reims | — |
| Terminated | Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Stero NCT01688882 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid NCT01571895 | Dompé Farmaceutici S.p.A | Phase 2 |
| Completed | Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids NCT01408550 | Nihon Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission NCT01265082 | National Taiwan University Hospital | — |
| Completed | Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous P NCT02883894 | CHU de Reims | — |
| Unknown | The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors NCT04469582 | University of Athens | — |
| Completed | Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid NCT00525616 | University Hospital, Rouen | Phase 3 |
| Completed | Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. NCT00809822 | Nihon Pharmaceutical Co., Ltd | Phase 2 |
| Completed | Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid NCT02313870 | University Hospital, Montpellier | Phase 3 |
| Unknown | Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid NCT00802243 | University Hospital, Limoges | Phase 2 |
| Completed | Efficacy and Safety of Omalizumab in Bullous Pemphigoid NCT00472030 | University of Iowa | Phase 4 |
| Completed | Rituximab in the Treatment of Patients With Bullous Pemphigoid NCT00286325 | Duke University | Phase 1 / Phase 2 |
| Completed | Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus NCT00213421 | University Hospital, Rouen | — |
| Completed | Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid NCT00431119 | University Hospital Muenster | Phase 2 |
| Approved For Marketing | Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid NCT05906706 | Regeneron Pharmaceuticals | — |